Lower abdominal adipose tissue cannabinoid type 1 receptor availability in young men with overweight
Obesity · 2023
DOI: 10.1002/oby.23770 ↗At a glance
Journal article in Obesity, 2023. Written by Laura Pekkarinen and 14 co-authors. Institution: Turku PET Centre, University of Turku, Turku, Finland. Major MEDLINE topics: Insulin Resistance, Diabetes Mellitus, Type 2, Cannabinoids. Cited 2 times so far (Crossref); 45 references. The full text is freely available (open access, CC BY 4.0). Funded by: Academy of Finland, Diabetestutkimussäätiö, Emil Aaltosen Säätiö.
Abstract (original language)
Objective
Cannabinoid type 1 receptors (CB1R) modulate feeding behavior and energy homeostasis, and the CB1R tone is dysgulated in obesity. This study aimed to investigate CB1R availability in peripheral tissue and brain in young men with overweight versus lean men.
Methods
Healthy males with high (HR, n = 16) or low (LR, n = 20) obesity risk were studied with fluoride 18–labeled FMPEP‐ d 2 positron emission tomography to quantify CB1R availability in abdominal adipose tissue, brown adipose tissue, muscle, and brain. Obesity risk was assessed by BMI, physical exercise habits, and familial obesity risk, including parental overweight, obesity, and type 2 diabetes. To assess insulin sensitivity, fluoro‐[ 18 F]‐deoxy‐2‐D‐glucose positron emission tomography during hyperinsulinemic‐euglycemic clamp was performed. Serum endocannabinoids were analyzed.
Results
CB1R availability in abdominal adipose tissue was lower in the HR than in the LR group, whereas no difference was found in other tissues. CB1R availability of abdominal adipose tissue and brain correlated positively with insulin sensitivity and negatively with unfavorable lipid profile, BMI, body adiposity, and inflammatory markers. Serum arachidonoyl glycerol concentration was associated with lower CB1R availability of the whole brain, unfavorable lipid profile, and higher serum inflammatory markers.
Conclusions
The results suggest endocannabinoid dysregulation already in the preobesity state.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Turku PET Centre, University of Turku, Turku, Finland.
- Department of Endocrinology, Turku University Hospital, Turku, Finland.
- Clinical Neurosciences, Turku University Hospital, Turku, Finland.
- MediCity Research Laboratory, University of Turku, Turku, Finland.
- Turku Bioscience Centre, University of Turku, Turku, Finland.
- Åbo Akademi University, Turku, Finland.
ORCID profiles: Laura Pekkarinen, Pirjo Nuutila
Funding
- Academy of Finland
- Diabetestutkimussäätiö
- Emil Aaltosen Säätiö
- Jenny ja Antti Wihurin Rahasto
- Orionin Tutkimussäätiö
Cite
APA
Pekkarinen, L., Kantonen, T., Oikonen, V., Haaparanta-Solin, M., Aarnio, R., Dickens, A. M., von Eyken, A., Latva-Rasku, A., Dadson, P., Kirjavainen, A. K., Rajander, J., Kalliokoski, K., Rönnemaa, T., Nummenmaa, L., & Nuutila, P. (2023). Lower abdominal adipose tissue cannabinoid type 1 receptor availability in young men with overweight. Obesity. https://doi.org/10.1002/oby.23770
Vancouver
Pekkarinen L, Kantonen T, Oikonen V, Haaparanta-Solin M, Aarnio R, Dickens AM, et al. Lower abdominal adipose tissue cannabinoid type 1 receptor availability in young men with overweight. Obesity. 2023. doi:10.1002/oby.23770
BibTeX
@article{Pekkarinen2023,
author = {Pekkarinen, Laura and Kantonen, Tatu and Oikonen, Vesa and Haaparanta-Solin, Merja and Aarnio, Richard and Dickens, Alex M and von Eyken, Annie and Latva-Rasku, Aino and Dadson, Prince and Kirjavainen, Anna K and Rajander, Johan and Kalliokoski, Kari and Rönnemaa, Tapani and Nummenmaa, Lauri and Nuutila, Pirjo},
title = {Lower abdominal adipose tissue cannabinoid type 1 receptor availability in young men with overweight},
journal = {Obesity},
year = {2023},
doi = {10.1002/oby.23770}
}
EUVIMED